Previous 10 | Next 10 |
Aptinyx (APTX) presents additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disorder ((PTSD)). The study, enrolling 153 patients, consisted of two four-week treatment stages comparing once-daily oral dosing of NYX-783—10mg or 50mg—...
Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented additional data from its exploratory Phase 2 study of NYX-783 in patients with post-traumatic stress disor...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences: 4 th Annual Neuroscience Inn...
Are These On Your List Of Penny Stocks To Buy Right Now? Everyone knows penny stocks can be risky. But with that higher risk comes the potential for higher rewards. Sure penny stocks under $0.50 that jump a quarter or more bring some big wins and great excitement to traders. How about t...
Hot Biotech Penny Stocks To Watch This Month Putting a list of penny stocks together? You might want to check for important dates. The biotech sector is well-known for giving the market plenty of lead time before releasing key information. Furthermore, the beauty of organizations like t...
Aptinyx (APTX) has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and dementia associated with Parkinson’s disease and dementia with Lewy bodies, following temporary suspension due to escalation of the COVID-19.The compa...
Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic Data readout from the Phase 2 cognitive impairment study expected in 2H 2022 Three Phase 2 data readouts expected over the next 12 to 18 months across the company...
Gainers: [[UEPS]] +4.61%. [[XGN]] +4.5%. [[DISCA]] +4.1%. [[CARG]] +3.3%. [[APTX]] +3.0%.Losers: [[EWTX]] -6.7%. [[NVAX]] -6.6%. [[AACG]] -6.5%. [[IKNA]] -5.9%. [[LSXMK]] -4.5%. For further details see: UEPS, XGN, IKNA and NVAX among after-hours movers
The following slide deck was published by Aptinyx Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Aptinyx Inc. 2020 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q4 2020 Earnings Call Mar 24, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q4 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...